Adjusted EBITDA reached $150 million, +1.8% Y/Y.
The company said that Q2 revenue and Adjusted EBITDA are consistent with internal expectations as it continues to overcome challenges resulting from industry shortages of CPAP equipment.
On a sequential basis, the adjusted EBITDA margin increased 110 basis points to 20.6%, as the company continues to manage through the inflationary environment and supply chain challenges.
The company reported EPS of $0.09, down from $0.12 a year ago and the consensus of $0.26.
Cash flow from operations was $103.5 million.
AdaptHealth says sleep categories showed strong sequential growth as the supply of PAP machines continues to improve relative to recent quarters.
Guidance: AdaptHealth reaffirms FY22 sales of $2.84 - $3.04 billion versus the consensus of $2.96 billion.
It forecasts adjusted EBITDA of $615-$675 million.
Price Action: AHCO shares are down 14.50% at $22 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.